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Enterovirus	71	is	reported	to	have	emerged	in	Cambodia	in	
2012;	at	least	54	children	with	severe	encephalitis	died	dur-
ing	that	outbreak.	We	used	serum	samples	collected	during	
2000–2011	to	show	that	the	virus	had	been	widespread	in	
the	country	for	at	least	a	decade	before	the	2012	outbreak.
In the Asia-Pacific region, human enterovirus 71 (EV71) is a widespread pathogen that causes hand, foot and 
mouth disease among children. Potentially fatal neurologic 
and systemic manifestations develop in a small proportion 
of patients (1).
In Cambodia during 2012, a disease outbreak charac-
terized by severe encephalitis with cardiovascular collapse 
and pulmonary edema seized international headlines and 
resulted in the death of at least 54 children; EV71 subgeno-
group C4 was identified as the cause (2). The large number 
of deaths during a short period was a concern for health 
authorities. To investigate whether EV71 had circulated 
in Cambodia before the 2012 outbreak, we retrospectively 
screened blood samples collected from children during 
2000–2011. 
The Study
We screened serum samples collected from inpatient chil-
dren in Cambodia through routine national dengue surveil-
lance. The study set was extracted from the Institut Pas-
teur in Cambodia biobank of strictly anonymized samples 
collected from 9,408 febrile inpatients during 2000–2011. 
Ethics clearance was obtained from the Cambodian Na-
tional Ethics Committee for Human Research before test-
ing commenced.
After exclusion of data entry errors, outliers in terms 
of year of participation, and insufficient data or samples, 
the database included 7,823 children 2–15 years of age for 
whom age, sex, and province of residence were document-
ed. To avoid any influence from maternal antibodies, we 
excluded children <2 years of age from the study. Prov-
inces were allocated to geographic quadrants and mapped 
by using ArcGIS 10 (Esri Co., Redlands, CA, USA) (online 
Technical Appendix Figure 1, http://wwwnc.cdc.gov/EID/
article/22/1/15-1323-Techapp1.pdf). Random sampling 
was applied by using Stata 11 (StataCorp LP, College Sta-
tion, TX, USA) with a representation of samples for each 
year. A total of 1,707 anonymized samples (1 sample/
child) were selected and tested. All available samples from 
the sparsely populated northeastern quadrant (4% of the 
dataset) were included. Because the southeastern quadrant 
(bordering Vietnam) is the most populated quadrant, sam-
ples were selected in approximate proportion to population 
(46% of the dataset). Samples from the southwestern (18% 
of dataset) and northwestern (31% of the dataset) quad-
rants, each of which borders Thailand, were selected pro-
portionally to represent a total of 48% from the quadrants 
bordering Thailand (Table).
The 1,707 serum samples were screened by use of a 
microneutralization assay to detect neutralizing antibodies 
against an EV71 strain (genotype C4a) isolated from an in-
fected child during the 2012 outbreak in Cambodia. The as-
say was conducted on Vero E6 cells by mixing 2-fold serial 
dilutions (1:8 to 1:8,192) of heat-inactivated human serum 
samples with 100 mL (2,000 50% tissue culture infective 
doses/mL) of the EV71 strain. Cytopathic effect was deter-
mined visually before and after staining with 2.5% crystal 
violet solution. All serum samples were tested in duplicate, 
and positive control serum was added to each reaction plate 
for quality control purposes. The lowest dilution at which 
cytopathic effect was observed in >50% of wells was con-
sidered the antibody titer of the serum sample. A titer of 
>1:16 was considered the cutoff for a positive antibody 
response and was a more stringent cutoff than that used 
in previously published EV71 seroprevalence studies, in 
which the cutoff was usually >1:8 (3–6).
To reconstruct the historical annual probability of in-
fection, we used information about the serostatus and age 
of the children. This reconstruction assumed that after 
infection, detectable antibody titers are long lasting; this 
method has been used to estimate the historical force of 
infection for other diseases, such as dengue (7). We esti-
mated a separate annual probability of infection for each 
year from 1994 through 2011. Because no patients in our 
dataset had been born before 1994, we could not estimate 
the force of infection before this time (online Technical 
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Appendix). Because samples included in this study were 
from children with a denguelike illness, rates of EV71 infec-
tion among study participants might not accurately reflect 
rates among all children in Cambodia. However, because 
an average of 87.8% of patients recruited by the National 
Dengue Surveillance Program had a laboratory-confirmed 
dengue infection (8), the febrile episode that triggered the 
hospitalization could be only slightly associated with EV71 
infection and thus would have negligible influence on the 
EV71 neutralizing titers of the patient population.
Among children in this study, the overall seropreva-
lence of EV71 neutralizing antibodies was 88.8%: 1,300 
(94.8%) of 1,371 (95% CI 93.5%–95.9%) among children 
2–15 years of age sampled during 2006–2011 and 216 
(64.3%) of 336 (95% CI 58.9%–69.4%) among those 2–7 
years of age sampled during 2000–2005 (Figure 1). Serop-
revalence did not vary substantially by age group. This pro-
file across age groups remained unchanged in more strin-
gent analyses with higher cutoff values (online Technical 
Appendix Figure 2) in which, despite levels of seropositiv-
ity decreasing with higher cutoff titers, the reduction was 
consistent across all age groups. Seroprevalence of EV71 
relative to sex did not differ significantly (89.8% among 
girls vs. 87.7% among boys; p = 0.18).
Epidemic curves derived from the seroprevalence data 
show the dynamics of infection for the whole country (Fig-
ure 2) and across the 4 quadrants (online Technical Ap-
pendix Figure 3). The reconstructed curves were coherent, 
showing large-scale, countrywide circulation of the virus 
since 2002. Seroprevalence peaks every 2–3 years indi-
cate a cyclical pattern of EV71 outbreaks. This pattern has 
been reported from other Asia-Pacific countries (9–11) and 
probably represents the time needed for establishment of a 
new cohort of immunologically naive patients. In countries 
with a larger population, such as China, infection might 
peak annually (12).
Despite our use of a more stringent cutoff value, the se-
roprevalence detected in our study was considerably higher 
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Table. Population	statistics	and	enterovirus	71	seroprevalence	among children	2–15	years	of	age,	by	geographic	quadrant,	Cambodia,	
2000–2011 
Quadrant Population	(%	seroprevalence)* No.	participants	(%	of	dataset) Overall	seroprevalence,	no.	(%) 
Northwest 2,785,308	(20.2) 535	(31.3) 488	(91.2) 
Northeast 1,445,009	(10.5) 76	(4.4) 64	(84.2) 
Southwest 3,831,832	(27.8) 314	(18.4) 271	(86.3) 
Southeast 5,703,047	(41.4) 782	(45.8) 693	(88.6) 
Total 13,765,196	(100) 1,707	(100) 1,516	(88.8) 
*All-age	population	in	2008	(census	nearest	to	retrospective	study	midpoint).	Data	from	the	National	Institute	of	Statistics,	Directorate	General	for Health,	
Cambodia	Demographic	ICF	Macro,	2011;	General	Population	Census	of	Cambodia,	2008;	and	Ministry	of	Planning,	2009. 
 
Figure 1.	Age-associated	
seroprevalence	of	enterovirus	71	
(EV71)	infection	in	Cambodia,	
estimated	by	detection	of	EV71	
seroneutralizing	antibodies	in	
inpatient	children	2–15	years	of	age,	
2000–2011.	Error	bars	indicate	95%	
CIs.	Serum	samples	were	collected	
from	routine	national	dengue	
surveillance	in	Cambodia.	
DISPATCHES
than that reported from previous studies in the region, dur-
ing which a cutoff of 1:8 was invariably used (3–6). If we 
had used a neutralization titer of 1:8, seroprevalence would 
have been 93.1% (n = 1,590 positive samples). Intense 
circulation of EV71 was therefore occurring in Cambodia 
long before the 2012 outbreak.
In Cambodia and other Asia-Pacific countries, other 
enteroviruses commonly cocirculate with EV71. Some of 
these strains, such as coxsackieviruses A6 and A16, have 
also been associated with severe neurologic illnesses in 
children. Previous studies have established that cross-neu-
tralization occurs among different EV71 strains and geno-
groups (13,14). However, there is no evidence of cross-
neutralization between EV71 and other enteroviruses (15). 
Cross-neutralization at high dilutions would probably not 
have generated a consistent profile of seropositivity across 
children of different ages (online Technical Appendix Fig-
ure 2). Thus, the high level of seropositivity observed in 
this study is probably specific for EV71.
Conclusions
Our data support the widespread circulation of EV71 
at least a decade before its reported emergence in 2012. 
Furthermore, reconstructed epidemic curves suggest that 
EV71 outbreaks occurred in a cyclical pattern in Cambo-
dia and that the virus infected large proportions of immu-
nologically naive children every 2–3 years. Before 2012, 
this circulation remained undetected, highlighting the need 
to further reinforce the surveillance systems in developing 
countries. Also needed is enhanced medical education for 
better identification of infectious diseases such as hand, 
foot and mouth disease, which, despite its association with 
relatively specific clinical signs, requires careful physical 
examination of patients. 
It is still unknown why so many severe cases were de-
tected during the 2012 EV71 outbreak in Cambodia. How-
ever, seroepidemiologic studies in other settings have also 
confirmed widespread circulation before outbreaks (5,9). 
For combatting this pathogen, developments in vaccines 
and antiviral drugs are urgently needed.
This study was supported by the Second Health Sector Support 
Program, Ministry of Health of the Kingdom of Cambodia, and 
the Asian Development Bank.
Dr. Horwood is the deputy-head of the Virology Unit at the 
Institut Pasteur in Cambodia. His research interests include mo-
lecular characterization and epidemiology of emerging tropical 
infectious diseases.
References
  1. Wang SM, Liu CC. Update of enterovirus 71 infection:  
epidemiology, pathogenesis and vaccine. Expert Rev Anti  
Infect Ther. 2014;12:447–56. http://dx.doi.org/10.1586/ 
14787210.2014.895666
  2. Human enterovirus 71–Cambodia: genotype C4. ProMED. 2012 
Jul 26 [cited 2015 Jun 2]. http://www.promedmail.org, archive no. 
20120726.1216290.
  3. Ang LW, Phoon MC, Wu Y, Cutter J, James L, Chow VT.  
The changing seroepidemiology of enterovirus 71 infection 
among children and adolescents in Singapore. BMC Infect Dis. 
2011;11:270. PubMed http://dx.doi.org/10.1186/1471-2334-11-270
  4. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, Zhu Q, et al.  
Seroepidemiology of enterovirus 71 infection prior to the 2011  
season in children in Shanghai. J Clin Virol. 2012;53:285–9.  
http://dx.doi.org/10.1016/j.jcv.2011.12.025
94	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	22,	No.	1,	January	2016
Figure 2.	Annual	probability	of	
enterovirus	71	infection	(EV71)	
in	Cambodia	during	1994–2011,	
estimated	by	detection	of	EV71	
seroneutralizing	antibodies	in	
inpatient	children	2–15	years	
of	age.	Serum	samples	were	
collected	from	routine	national	
dengue	surveillance	in	Cambodia.
Human	Enterovirus	71	among	Children,	Cambodia
  5. Li W, Yi L, Su J, Lu J, Ke C, Zeng H, et al. Seroprevalence of  
human enterovirus 71 and coxsackievirus A16 in Guangdong, 
China, in pre- and post-2010 HFMD epidemic period.  
PLoS ONE. 2013;8:e80515. http://dx.doi.org/10.1371/journal.
pone.0080515
  6. Linsuwanon P, Puenpa J, Huang SW, Wang YF,  
Mauleekoonphairoj J, Wang JR, et al. Epidemiology and  
seroepidemiology of human enterovirus 71 among Thai  
populations. J Biomed Sci. 2014;21:16. http://dx.doi.org/ 
10.1186/1423-0127-21-16
  7. Ferguson NM, Donnelly CA, Anderson RM. Transmission  
dynamics and epidemiology of dengue: insights from age-stratified 
sero-prevalence surveys. Philos Trans R Soc Lond B Biol Sci. 
1999;354:757–68. http://dx.doi.org/10.1098/rstb.1999.0428
  8. Huy R, Buchy P, Conan A, Ngan C, Ong S, Ali R, et al.  
National dengue surveillance in Cambodia 1980–2008:  
epidemiological and virological trends and the impact of vector 
control. Bull World Health Organ. 2010;88:650–7.  
http://dx.doi.org/10.2471/BLT.09.073908
  9. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year 
study of epidemiologic features of enterovirus 71 infection in 
Taiwan. Am J Trop Med Hyg. 2007;77:188–91. 
10. Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, et al. 
Sentinel surveillance for human enterovirus 71 in Sarawak,  
Malaysia: lessons from the first 7 years. BMC Public Health. 
2006;6:180. http://dx.doi.org/10.1186/1471-2458-6-180
11. Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E,  
Nakamura K, et al. Genetic changes of coxsackievirus A16 and 
enterovirus 71 isolated from hand, foot, and mouth disease patients 
in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009; 
62:254–9. 
12. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al.  
Hand, foot, and mouth disease in China, 2008–12: an  
epidemiological study. Lancet Infect Dis. 2014;14:308–18.  
http://dx.doi.org/10.1016/S1473-3099(13)70342-6
13. Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T,  
et al. Cross-antigenicity among EV71 strains from different  
genogroups isolated in Yamagata, Japan, between 1990 and  
2007. Vaccine. 2009;27:3153–8. http://dx.doi.org/10.1016/ 
j.vaccine.2009.03.060
14. Huang ML, Chiang PS, Chia MY, Luo ST, Chang LY, Lin TY,  
et al. Cross-reactive neutralizing antibody responses to enterovirus 
71 infections in young children: implications for vaccine  
development. PLoS Negl Trop Dis. 2013;7:e2067.  
http://dx.doi.org/10.1371/journal.pntd.0002067
15. Huang WC, Huang LM, Kao CL, Lu CY, Shao PL, Cheng AL,  
et al. Seroprevalence of enterovirus 71 and no evidence of cross-
protection of enterovirus 71 antibody against the other  
enteroviruses in kindergarten children in Taipei city.  
J Microbiol Immunol Infect. 2012;45:96–101.  
http://dx.doi.org/10.1016/j.jmii.2011.09.025
Address for correspondence: Philippe Buchy, GlaxoSmithKline 
Vaccines, Gateway West, 150 Beach Rd, 189720 Singapore; email: 
buchyphilippe@hotmail.com
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	22,	No.	1,	January	2016	 95
